Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T03:52:04.548Z Has data issue: false hasContentIssue false
  • English
  • Français

Sudden cardiac arrest following ventricular fibrillation attributed to anabolic steroid use in an adolescent

Published online by Cambridge University Press:  16 March 2016

Jana Lichtenfeld ,
Barbara J. Deal  and
Susan Crawford
Jana Lichtenfeld*
Affiliation:
Department of Pediatrics, St. Louis Children’s Hospital, St. Louis, Missouri, United States of America
Barbara J. Deal
Affiliation:
Department of Pediatrics, Division of Cardiology, Lurie Children’s Hospital, Chicago, Illinois, United States of America
Susan Crawford
Affiliation:
Midwestern University, Downers Grove, Illinois, United States of America
*
Correspondence to: J. Lichtenfeld, MD, 1 Children’s Place, St. Louis, MO 63110, United States of America. Tel: +001 312 399 5262; Fax: + 001 314 454 4102; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Anabolic androgenic steroids are synthetic derivatives of testosterone that promote the growth of skeletal muscles and have many recognised cardiovascular effects. We report the clinical presentation and pathological findings of an adolescent male whose sudden cardiac arrest following ventricular fibrillation was attributed to anabolic androgenic steroid use. The age of our patient reflects the usage of anabolic androgenic steroids among younger athletes and highlights the need for increased awareness among practitioners.

Keywords

Anabolic androgenic steroidshypertrophic cardiomyopathycardiac arrestventricular fibrillation
Type
Brief Reports
Information
Cardiology in the Young , Volume 26 , Issue 5 , June 2016 , pp. 996 - 998
Check for updates
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Van Amsterdam, J, Opperhuizen, A, Hartgens, F. Adverse health effects of anabolic–androgenic steroids. Regul Toxicol Pharmacol 2010; 57: 117–123.Google Scholar
2. Dickerman, RD, Schaller, F, Prather, I, McConathy, WJ. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 1995; 86: 172–173.Google Scholar
3. Di Paolo, M, Agozzino, M, Toni, C, et al. Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol 2007; 114: 114–117.Google Scholar
4. Nieminen, MS, Ramo, MP, Viitasalo, M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996; 17: 1576–1583.Google Scholar
5. Dickerman, RD, Schaller, F, Zachariah, NY, McConathy, WJ. Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sport Med 1997; 7: 90–93.Google Scholar
6. Achar, S, Rostamian, A, Narayan, SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 2010; 106: 893–901.CrossRefGoogle ScholarPubMed
7. Johnston, LD, O’Malley, PM, Miech, RA, Bachman, JG, Schulenberg, JE. Monitoring the Future National Survey Results on Drug Use: 1975–2013: Overview, Key Findings on Adolescent Drug Use. Ann Arbor, Institute for Social Research, The University of Michigan, 2014, 84pp.Google Scholar
8. Hoffman, JR, Faigenbaum, AD, Ratamess, NA, Ross, R, Kang, J, Tenenbaum, G. Nutritional supplementation and anabolic steroid use in adolescents. Med Sci Sports Exerc 2008; 40: 15–24.Google Scholar